BioPharma Drive: Drug Pricing
OCTOBER 31, 2023
Expert advisers are reviewing the companies’ case for approval of what could be the first medicine based on the gene editing technology. Follow their discussion here.
Drug Target Review
NOVEMBER 1, 2023
Autotaxin (ATX) is a 99-125 kDa lysophospholipase D involved in a large range of physiological and pathological processes. 1 This critical enzyme is part of the nucleotide pyrophosphatase/ phosphodiesterase family and is also referred to as ENPP2. Five ATX isoforms have been identified, with ATX-b expressed in most human tissues and ATX-g specific to the central nervous system.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Science Daily: Pharmacology News
OCTOBER 31, 2023
A new paper revealed that human activities are making Earth's air, soil and freshwater saltier, which could pose an 'existential threat' if current trends continue. Geologic and hydrologic processes bring salts to Earth's surface over time, but human activities such as mining and land development are rapidly accelerating this natural 'salt cycle.
Drugs.com
NOVEMBER 3, 2023
THURSDAY, Nov. 2, 2023 -- A procedure to treat the irregular heart rhythm condition known as atrial fibrillation (a-fib) works just as well for women as it does for men, new research shows. The technology, called pulsed field ablation (PFA), can be.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioPharma Drive: Drug Pricing
OCTOBER 31, 2023
The high-profile meeting focused on the theoretical risks of CRISPR gene editing, as both the FDA and its advisory committee appeared convinced by the efficacy of the companies’ exa-cel treatment.
Broad Institute
NOVEMBER 2, 2023
Q&A: How generative AI could help accelerate biomedical research By Corie Lok November 2, 2023 Breadcrumb Home Q&A: How generative AI could help accelerate biomedical research A machine learning and AI expert discusses how generative AI could be used not just to write emails and computer code, but also to analyze biological data. By Corie Lok November 2, 2023 Credit: Maria Nemchuk, Broad Communications Mehrtash Babadi is director of computational methods in Broad's Data Sciences Platform The re
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drugs.com
NOVEMBER 3, 2023
FRIDAY, Nov. 3, 2023 -- The first new antibiotic for gonorrhea — the second most common sexually transmitted disease — has shown promise in a clinical trial. That news should come as a relief to public health experts, because gonorrhea.
BioPharma Drive: Drug Pricing
NOVEMBER 3, 2023
The company recorded a net loss in the third quarter as it “resizes” its manufacturing footprint, and now expects revenue to come in at low end of its previous guidance.
Drug Discovery Today
NOVEMBER 1, 2023
Investors need confidence and predictability if they are to invest in the fight against antibiotic resistance, finds a new report.
Drug Target Review
NOVEMBER 2, 2023
Most people have the same genetic information in every cell of their body. However, usually during foetal development, people can develop two or more genetically diverse set of cells. Known as mosaicism, occasionally one of those groups of cells has genetic changes that may cause disorders or diseases. Previous research has shown that mosaicism in the brain is an important contributor to epilepsy, so neurologists, neurosurgeons and genomic experts have collaborated to assess mosaicism in brain t
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drugs.com
NOVEMBER 3, 2023
THURSDAY, Nov. 2, 2023 -- Cardinal Health, Inc. is voluntarily recalling certain LEADER brand eyedrops because they may cause eye infections. The U.S. Food and Drug Administration informed the Dublin, Ohio, company that agency investigators found.
Perficient: Drug Development
OCTOBER 30, 2023
Are you a Healthcare Business Leader stressing over how much you should use AI? Don’t be. I’m certain you have a roadmap with some bodacious goals on them. You want to increase engagement and access to high quality care and drive down healthcare costs, right? Although AI isn’t a magic wand, we can finally start to think bigger and shorten our roadmaps.
addgene Blog
NOVEMBER 2, 2023
There can be no doubt that CRISPR/Cas9 technology has been a breakthrough for the genome-editing field and the greater scientific community. In 2014, we wrote a blog post on CRISPR’s potential for correcting monogenetic diseases. Now, almost 10 years later, CRISPR’s potential for treatment is no longer an accurate descriptor; progress in clinical therapy is more fitting, so it is time to update our post.
Drug Target Review
NOVEMBER 3, 2023
Through the process of differentiation, stem cells develop into different cell types of the human gut. Organoid group (Hubrecht Institute) researchers, collaborating with researchers at the Princess Máxima Center and Maastricht University, used gut organoids to perform a systematic CRISPR screening of 1800 human transcription factors. They identified ZNF800 as a key regulator of the differentiation of a specific gut cell type, the enteroendocrine cells.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drugs.com
NOVEMBER 2, 2023
WEDNESDAY, Nov. 1, 2023 -- Newer oral medications for rheumatoid arthritis (RA) do work quite well in the "real world," despite some doubts that they would, according to a new study. The study, of 622 adults with RA, found that most were doing well.
Perficient: Drug Development
OCTOBER 30, 2023
Success and failure – just like hot and cold, light and darkness, love and hate, or good and evil – these represent the ends of a familiar spectrum. Countless philosophical works have pondered these seemingly opposing concepts. My favorite view for all such opposites is that you cannot understand one without the other. They are more complementary than they are contradictory.
Drug Discovery Today
NOVEMBER 2, 2023
Over two million doses of illegally traded medicines valued at almost £5m seized so far this year.
Drug Target Review
OCTOBER 31, 2023
Can you tell us about your journey in the field of STEM and the challenges you encountered along the way? What inspired you to pursue a career in STEM, and how did you overcome any obstacles or biases you may have faced? Someone with a fighter spirit and FDA regulatory experience had to fight for it and I decided to take on that role. I always knew I wanted to study biology.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drugs.com
NOVEMBER 3, 2023
FRIDAY, Nov. 3, 2023 -- Put down the saltshaker — especially if you’re at risk of type 2 diabetes. While the condition brings to mind the need to avoid sugar, a new study links it to frequent salt consumption. “We already know.
PLOS: DNA Science
NOVEMBER 2, 2023
The email from my former neighbor Shaun Kuczek was unexpected. “Hi Ricki! My Dad passed in July, and we’re cleaning out his house. He was a biology teacher for 35 years and I have 40 or so old biology textbooks. I remember that you write biology textbooks, and maybe you have an idea of a way to pass them along? They’re all old, 1950s, 1960s.
Broad Institute
NOVEMBER 2, 2023
Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates. By Broad Communications November 2, 2023 Related News Bayer, Broad expand partnership to advance cancer drug discovery research Broad Institute and Bayer join forces to develop novel treatment options in ca
biobide
NOVEMBER 3, 2023
Background on the tobacco industry As of 2022, the global tobacco market was valued at approximately 867.55 USD billion, and it is projected to experience a 2.1% annual growth from 2023 to 2024. This has been attributed to rising consumption in the developing regions of Asia and Africa , but also to the trend toward new tobacco products launched, attracting a new demographic of consumers.
Drugs.com
NOVEMBER 3, 2023
THURSDAY, Nov. 2, 2023 -- A new study on Clostridioides difficile infections finds that choosing an alternative antibiotic for high-risk patients with pneumonia can reduce infection risk. C. diff infections can be deadly, and they are often.
KIF1A
OCTOBER 28, 2023
#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. KIF1A-Related Research Genetic overlap between ALS and other neurodegenerative or neuromuscular disorders How do you define a disease?
BioPharma Drive: Drug Pricing
NOVEMBER 2, 2023
The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.
ProRelix Research
NOVEMBER 2, 2023
Although clinical trials provide useful information regarding the efficacy and safety of new drugs, biological products, and medical devices, the information captured through them is not all-encompassing. Limited patient populations, […] The post Post-Marketing Surveillance Strategies appeared first on ProRelix Research.
Drugs.com
NOVEMBER 2, 2023
WEDNESDAY, Nov. 1, 2023 -- Many antibiotics long used to treat common childhood infections are no longer effective because of antibiotic resistance. The authors of a new study say global guidelines on antibiotic use need to be updated to reflect.
Perficient: Drug Development
OCTOBER 30, 2023
September is Hunger Action Month (HAM) when Feeding America , a Perficient community partner, organizes a campaign to spread awareness about food insecurity. To support these efforts, Perficient Giving ERG organized a friendly HAM competition to encourage colleagues worldwide to donate non-perishable food items to their local food banks. Offices that collect the most donations and have the biggest impact qualify for special recognition as HAM champions!
BioPharma Drive: Drug Pricing
OCTOBER 30, 2023
Yet Sarepta said it still plans to ask the FDA to expand regulatory clearance of Elevidys, which was granted an accelerated approval by the FDA in June.
Drug Patent Watch
OCTOBER 30, 2023
Over the past two decades, Bayer Pharma has developed an in silico absorption, distribution, metabolism, and excretion (ADMET) platform with the aim of generating models for various pharmacokinetic and physicochemical… The post Advancements in In Silico ADMET Modeling: A 20-Year Journey of Machine Learning in Drug Discovery at Bayer Pharma appeared first on DrugPatentWatch - Make Better Decisions.
Drugs.com
OCTOBER 31, 2023
MONDAY, Oct. 30, 2023 -- A cheap, do-it-yourself air purifier is powerful enough to effectively protect a home from free-floating flu and COVID-19 viruses, according to test results from the U.S. Environmental Protection Agency. The filter, crafted.
SCIENMAG: Medicine & Health
OCTOBER 31, 2023
CHAPEL HILL, N.C. – The lungs were once at the forefront of SARS-Cov-2 research, but as reports of organ failure and other serious complications poured in, scientists set out to discover how and why the respiratory virus was causing serious damage to the body’s major organs, including the lungs.
BioPharma Drive: Drug Pricing
OCTOBER 30, 2023
The venture firm has supported a number of approved medicines with its co-development strategy, including Pfizer’s Besponsa and Apellis’ Empaveli.
Expert insights. Personalized for you.
131 
Let's personalize your content